Suzuken Co., Ltd. (SZUKF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Suzuken Co., Ltd. (SZUKF) trades at $30.30. Suzuken Co. , Ltd. is a Japanese pharmaceutical wholesaler operating across four segments: pharmaceutical distribution, manufacturing, pharmacy, and healthcare-related services. Market cap: $2.05B, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 17, 2026Analyst Coverage for SZUKF: SZUKF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SZUKF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
Not enough scored data yet to form a council read on SZUKF.
How is this calculated? →Suzuken Co., Ltd. (SZUKF) Healthcare & Pipeline Overview
Suzuken Co., Ltd., established in 1932, is a diversified healthcare company primarily engaged in pharmaceutical wholesale distribution in Japan and internationally. With a market capitalization of $2.05B, Suzuken also manufactures pharmaceuticals, operates pharmacies, and provides healthcare-related services, positioning itself as a comprehensive healthcare solutions provider.
What Is the Investment Thesis for SZUKF?
Suzuken Co., Ltd. presents a stable investment opportunity within the healthcare sector, characterized by its diversified business model and established presence in the Japanese pharmaceutical market. With a P/E ratio of 11.83 and a dividend yield of 1.69%, the company offers a blend of value and income. A key value driver is its comprehensive service offering, spanning pharmaceutical distribution, manufacturing, and pharmacy operations. Ongoing catalysts include the increasing demand for healthcare services in Japan due to its aging population and the growing prevalence of chronic diseases like diabetes and kidney disease, areas where Suzuken has a manufacturing focus. However, potential risks include regulatory changes in the pharmaceutical industry and competitive pressures from other distributors and manufacturers. The company's low beta of 0.15 suggests relatively low volatility compared to the broader market.
Based on FMP financials and quantitative analysis
SZUKF Key Highlights
Market capitalization of $2.05B reflects Suzuken's established position in the healthcare distribution market.
- P/E ratio of 11.83 indicates a potentially undervalued stock compared to industry peers.
- Profit margin of 1.4% demonstrates the company's ability to generate earnings, although there is room for improvement.
- Gross margin of 7.8% highlights the efficiency of Suzuken's supply chain and pricing strategies.
- Dividend yield of 1.69% provides a steady income stream for investors.
Who Are SZUKF's Competitors?
SZUKF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ALFRY Alfresa Holdings Corporation | $13.55 | +0.00% | $2.46B | 49 |
| DRWKF Drägerwerk AG & Co. KGaA | $100.47 | +0.00% | $1.88B | 50 |
| EBOSY EBOS Group Limited | $26.00 | +0.00% | $1.33B | 42 |
| IUSDF AS ONE Corporation | $14.00 | +0.00% | $998M | 46 |
| MEDGF Medacta Group S.A. | $160.00 | +0.00% | $3.19B | 55 |
| GRDN Guardian Pharmacy Services, Inc. | $37.48 | -1.29% | $2.37B | 96 |
| PBH Prestige Consumer Healthcare Inc. | $50.52 | -2.24% | $2.39B | 64 |
| PDCO Patterson Companies, Inc. | $31.33 | -0.90% | $2.77B | 42 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SZUKF's Key Strengths?
Diversified business model with multiple revenue streams.
- Established distribution network in Japan.
- Strong relationships with pharmaceutical manufacturers and medical institutions.
- Expertise in handling specialized pharmaceuticals.
What Are SZUKF's Weaknesses?
Relatively low profit margin compared to industry peers.
- Concentration of operations in the Japanese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited brand recognition outside of Japan.
What Could Drive SZUKF Stock Higher?
Increasing demand for healthcare services in Japan due to its aging population.
- Growing prevalence of chronic diseases like diabetes and kidney disease, areas where Suzuken has a manufacturing focus.
- Potential for strategic partnerships to expand service offerings and geographic reach.
- Digital transformation initiatives to improve supply chain efficiency and reduce costs.
- International expansion into new markets to diversify revenue streams.
What Are the Key Risks for SZUKF?
Regulatory changes in the pharmaceutical industry impacting pricing and distribution.
- Competitive pressures from other pharmaceutical distributors and manufacturers.
- Economic downturns affecting healthcare spending and demand for pharmaceuticals.
- Fluctuations in currency exchange rates impacting international operations.
- Disruptions in the supply chain due to geopolitical events or natural disasters.
What Are the Growth Opportunities for SZUKF?
- Expansion of Pharmaceutical Manufacturing: Suzuken's focus on manufacturing drugs for diabetes and kidney diseases positions it to capitalize on the growing prevalence of these conditions globally. The global diabetes market is projected to reach $49 billion by 2027, offering a significant growth opportunity for Suzuken. By investing in research and development and expanding its manufacturing capacity, Suzuken can increase its market share and improve its profitability. Timeline: Ongoing.
- Growth in Healthcare-Related Services: The Healthcare-Related Services segment, which includes manufacturer support and nursing care services, presents another avenue for growth. The increasing demand for home healthcare and support services for the elderly population in Japan creates a favorable environment for this segment. By expanding its service offerings and geographic reach, Suzuken can capture a larger share of this market. Timeline: Ongoing.
- Strategic Partnerships and Collaborations: Suzuken's collaboration with Bushu Pharmaceuticals Ltd. to provide contract specialty drug services demonstrates the potential of strategic partnerships to drive growth. By forming alliances with other companies in the healthcare sector, Suzuken can expand its capabilities, access new markets, and enhance its competitive position. Timeline: Ongoing.
- Digital Transformation of Distribution: Implementing advanced technologies such as AI and blockchain to optimize its supply chain and improve efficiency can drive growth. The adoption of digital solutions can reduce costs, improve inventory management, and enhance customer service. This can lead to increased market share and improved profitability. Timeline: Upcoming.
- International Expansion: While primarily focused on the Japanese market, Suzuken has the potential to expand its operations internationally. By targeting specific markets with high growth potential and adapting its business model to local conditions, Suzuken can diversify its revenue streams and reduce its reliance on the Japanese market. Timeline: Potential.
What Threats Does SZUKF Face?
- Increasing competition from other pharmaceutical distributors.
- Pricing pressures from generic drugs and biosimilars.
- Changes in government regulations and healthcare policies.
- Economic downturns affecting healthcare spending.
What Are SZUKF's Competitive Advantages?
- Established distribution network in Japan.
- Long-standing relationships with pharmaceutical manufacturers and medical institutions.
- Diversified business model spanning distribution, manufacturing, and services.
- Expertise in handling specialized pharmaceuticals, including orphan drugs.
What Does SZUKF Do?
Founded in 1932 and headquartered in Nagoya, Japan, Suzuken Co., Ltd. has evolved into a multifaceted healthcare company. Initially focused on pharmaceutical wholesale, Suzuken has expanded its operations to include pharmaceutical manufacturing, pharmacy services, and a range of healthcare-related services. The company's Pharmaceutical Distribution Business segment is the core of its operations, procuring and supplying ethical drugs, diagnostic reagents, medical equipment, and other health-related items to medical institutions and pharmacies. This segment serves as a critical link between pharmaceutical manufacturers and healthcare providers. Expanding beyond distribution, Suzuken's Pharmaceutical Manufacturing Business segment focuses on the research, development, manufacturing, and marketing of ethical pharmaceuticals and diagnostic products, particularly in the areas of diabetes and kidney diseases. This vertical integration allows Suzuken to capture additional value and address specific healthcare needs. The Pharmacy Business segment provides services through family pharmacists, aiming to improve local pharmacy operations and provide educational support. This segment emphasizes patient-centric care and community health. The Healthcare-Related Services Business segment offers a diverse portfolio of services, including manufacturer support, contract distribution for manufacturers, distribution of orphan drugs, and nursing care services. It also develops, manufactures, and sells medical devices and health promotion equipment. Suzuken also publishes medical magazines for medical institutions, further solidifying its position as a comprehensive healthcare solutions provider. The collaboration with Bushu Pharmaceuticals Ltd. enhances its capabilities in contract specialty drug services.
What Products and Services Does SZUKF Offer?
- Wholesale distribution of pharmaceuticals to medical institutions and pharmacies.
- Manufacturing of ethical pharmaceuticals and diagnostic products.
- Operation of pharmacies providing services through family pharmacists.
- Provision of manufacturer support services, including contract distribution.
- Distribution of orphan drugs.
- Provision of nursing care services.
- Development, manufacturing, and sale of medical devices and health promotion equipment.
- Publishing medical magazines for medical institutions.
How Does SZUKF Make Money?
- Procures pharmaceuticals and medical supplies from manufacturers.
- Distributes products to medical institutions and pharmacies.
- Generates revenue through wholesale distribution, manufacturing, and service fees.
- Focuses on providing comprehensive healthcare solutions to its customers.
What Industry Does SZUKF Operate In?
Suzuken Co., Ltd. operates within the healthcare distribution industry, a sector experiencing steady growth driven by aging populations and increasing healthcare expenditures. The Japanese pharmaceutical market is characterized by stringent regulations and a focus on quality and safety. Suzuken competes with other major pharmaceutical distributors, as well as manufacturers who are increasingly engaging in direct distribution. The industry is also influenced by trends such as the growing demand for specialty drugs and the increasing adoption of digital technologies to improve supply chain efficiency and patient care.
Who Are SZUKF's Key Customers?
- Medical institutions (hospitals, clinics).
- Pharmacies.
- Pharmaceutical manufacturers.
- Patients requiring nursing care services.
Key Financial Metrics
Return on equity for Suzuken Co., Ltd. stands at 9.2%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is 3.2%, showing how much profit it generates from its asset base. SZUKF trades at a trailing price-to-earnings ratio of 8.97, below the Healthcare sector average of ~23x. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.22 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is 11.2%, the inverse of the P/E and a quick read on earnings relative to price.
Suzuken Co., Ltd. (SZUKF) Valuation Context
Valued at $2.05B, SZUKF is classified as a mid-cap stock.
Company Profile
Suzuken Co., Ltd. operates in the Medical - Distribution industry within the Healthcare sector. It is headquartered in Nagoya, JP. The company is led by CEO Shigeru Asano. SZUKF has traded publicly since 2013.
Financial Health
Suzuken Co., Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.09 places it in the safe zone, indicating low near-term bankruptcy risk.
Forward Outlook
Wall Street analysts project Suzuken Co., Ltd. revenue of about $2.49T for fiscal 2026, with EPS near $502.40. The estimate reflects 4 contributing analysts.
SZUKF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2026
Bull Case vs Bear Case
Bull Case
- Diversified business model with multiple revenue streams.
- Established distribution network in Japan.
- Strong relationships with pharmaceutical manufacturers and medical institutions.
- Expertise in handling specialized pharmaceuticals.
Bear Case
- Relatively low profit margin compared to industry peers.
- Concentration of operations in the Japanese market.
- Exposure to regulatory changes in the pharmaceutical industry.
- Limited brand recognition outside of Japan.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
SZUKF Latest News
No recent news available for SZUKF.
SZUKF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SZUKF.
Price Targets
Wall Street price target analysis for SZUKF.
SZUKF MoonshotScore
What does this score mean?
The MoonshotScore rates SZUKF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Shigeru Asano
CEO
Shigeru Asano serves as the CEO of Suzuken Co., Ltd., leading a workforce of over 13,000 employees. His career within Suzuken has spanned various leadership roles, providing him with a deep understanding of the company's operations and strategic direction. He has been instrumental in guiding the company through evolving market dynamics and technological advancements in the healthcare sector. His expertise lies in pharmaceutical distribution, manufacturing, and healthcare services.
Track Record: Under Shigeru Asano's leadership, Suzuken has focused on expanding its healthcare-related services and strengthening its position in the pharmaceutical manufacturing sector. Key achievements include strategic collaborations to enhance specialty drug services and initiatives to improve operational efficiency through digital transformation. He has also overseen the company's efforts to adapt to changing regulatory landscapes and evolving customer needs.
SZUKF OTC Market Information
The OTC Other tier, where Suzuken Co., Ltd. (SZUKF) trades, represents the lowest of the OTC market tiers. Companies in this tier often have limited or no reporting requirements, meaning they may not provide regular financial disclosures to the public. This lack of transparency increases the risk for investors, as it is more difficult to assess the company's financial health and performance compared to companies listed on major exchanges like the NYSE or NASDAQ, which have strict listing and reporting standards.
- OTC Tier: OTC Other
- Limited financial disclosure increases the risk of investing in SZUKF.
- Lower trading volume and wider bid-ask spreads can lead to price volatility.
- OTC stocks are more susceptible to fraud and manipulation.
- The OTC Other tier has minimal listing requirements, increasing the risk of investing in less established or financially stable companies.
- Difficulty in obtaining reliable information about the company's operations and financial performance.
- Verify the company's registration and legal standing.
- Investigate the background and experience of the company's management team.
- Attempt to obtain and review any available financial statements or reports.
- Assess the company's business model and competitive landscape.
- Understand the risks associated with investing in OTC stocks.
- Consult with a financial advisor before making any investment decisions.
- Check for any regulatory actions or legal disputes involving the company.
- Suzuken's long operating history since 1932 suggests a degree of stability.
- The company's established presence in the Japanese pharmaceutical market provides some reassurance.
- The company's diversified business model reduces reliance on a single revenue stream.
- Collaboration with Bushu Pharmaceuticals Ltd. indicates industry recognition and partnerships.
- The company's size, with over 13,000 employees, suggests a substantial operation.
What Investors Ask About Suzuken Co., Ltd. (SZUKF) — Healthcare
What does Suzuken Co., Ltd. do?
Suzuken Co., Ltd. operates as a comprehensive healthcare solutions provider, primarily engaged in the wholesale distribution of pharmaceuticals in Japan and internationally. Beyond distribution, the company manufactures ethical pharmaceuticals and diagnostic products, particularly for diabetes and kidney diseases. Suzuken also operates pharmacies, providing services through family pharmacists, and offers healthcare-related services such as manufacturer support, contract distribution, and nursing care.
What are the main risks for SZUKF?
The main risks for Suzuken Co., Ltd. include regulatory changes in the pharmaceutical industry, which can impact pricing and distribution practices. Increased competition from other pharmaceutical distributors and manufacturers could erode market share and profitability. Economic downturns may affect healthcare spending and demand for pharmaceuticals.
What are the key factors to evaluate for SZUKF?
Evaluate SZUKF on fundamentals, analyst consensus, and risk factors. Suzuken Co., Ltd. presents a stable investment opportunity within the healthcare sector, characterized by its diversified business model and established presence in the Japanese pharmaceutical market. Not financial advice.
How frequently does SZUKF data refresh on this page?
SZUKF's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SZUKF's recent stock price performance?
Suzuken Co., Ltd. (SZUKF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Diversified business model with multiple revenue streams. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SZUKF overvalued or undervalued right now?
Suzuken Co., Ltd. (SZUKF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research SZUKF before investing?
Before investing in Suzuken Co., Ltd. (SZUKF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding SZUKF to a portfolio?
Key strength of Suzuken Co., Ltd. (SZUKF): Diversified business model with multiple revenue streams. Weigh rewards against risks and diversify. Not financial advice.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide further insights.